Literature DB >> 17430151

Triple reuptake inhibitors ("broad spectrum" antidepressants).

Phil Skolnick1, Anthony S Basile.   

Abstract

The majority of antidepressants in current use inhibit the uptake of serotonin and/or norepinephrine. Drugs inhibiting the uptake of serotonin, norepinephrine and dopamine (triple reuptake inhibitors) may offer therapeutic advantages compared to single and/or dual reuptake inhibitors. This review provides a rationale for developing this class of compound and describes the results of preclinical and clinical studies with a family of triple reuptake inhibitors.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17430151     DOI： 10.2174/187152707780363285

Source DB:  PubMed          Journal:  CNS Neurol Disord Drug Targets        ISSN： 1871-5273            Impact factor:   4.388


  8 in total

1.  The secrets of a successful clinical trial: compliance, compliance, and compliance.

Authors:  Pál Czobor; Phil Skolnick
Journal:  Mol Interv       Date:  2011-04

2.  Triple monoamine uptake inhibitors demonstrate a pharmacologic association between excessive drinking and impulsivity in high-alcohol-preferring (HAP) mice.

Authors:  David S O'Tousa; Kaitlin T Warnock; Liana M Matson; Ojas A Namjoshi; Michael Van Linn; Veera Venkata Tiruveedhula; Meredith E Halcomb; James Cook; Nicholas J Grahame; Harry L June
Journal:  Addict Biol       Date:  2013-10-13       Impact factor: 4.280

3.  Further structure-activity relationship studies on 4-((((3S,6S)-6-benzhydryltetrahydro-2H-pyran-3-yl)amino)methyl)phenol: identification of compounds with triple uptake inhibitory activity as potential antidepressant agents.

Authors:  Bhaskar Gopishetty; Stuart Hazeldine; Soumava Santra; Mark Johnson; Gyan Modi; Solav Ali; Juan Zhen; Maarten Reith; Aloke Dutta
Journal:  J Med Chem       Date:  2011-03-29       Impact factor: 7.446

4.  Effects of the triple monoamine uptake inhibitor DOV 102,677 on alcohol-motivated responding and antidepressant activity in alcohol-preferring (P) rats.

Authors:  Andrew R S T Yang; Heon S Yi; Kaitlin T Warnock; Jacek Mamczarz; Harry L June; Nikhil Mallick; Philip A Krieter; Leonardo Tonelli; Phil Skolnick; Anthony S Basile; Harry L June
Journal:  Alcohol Clin Exp Res       Date:  2011-12-07       Impact factor: 3.455

5.  Preclinical evaluation of the abuse potential of the analgesic bicifadine.

Authors:  Katherine L Nicholson; Robert L Balster; Krystyna Golembiowska; Magdalena Kowalska; Joseph P Tizzano; Phil Skolnick; Anthony S Basile
Journal:  J Pharmacol Exp Ther       Date:  2009-04-08       Impact factor: 4.030

6.  Amitifadine, a triple monoamine uptake inhibitor, reduces binge drinking and negative affect in an animal model of co-occurring alcoholism and depression symptomatology.

Authors:  Kaitlin T Warnock; Andrew R S T Yang; Heon S Yi; Harry L June; Timothy Kelly; Anthony S Basile; Phil Skolnick; Harry L June
Journal:  Pharmacol Biochem Behav       Date:  2012-11       Impact factor: 3.533

7.  Antidepressant-like Effects of LPM580153, A Novel Potent Triple Reuptake Inhibitor.

Authors:  Fangxi Zhang; Jing Shao; Jingwei Tian; Yan Zhong; Liang Ye; Xiangjing Meng; Qiaofeng Liu; Hongbo Wang
Journal:  Sci Rep       Date:  2016-04-07       Impact factor: 4.379

8.  LPM580098, a Novel Triple Reuptake Inhibitor of Serotonin, Noradrenaline, and Dopamine, Attenuates Neuropathic Pain.

Authors:  Nannan Li; Chunmei Li; Rui Han; Yu Wang; Mina Yang; Hongbo Wang; Jingwei Tian
Journal:  Front Pharmacol       Date:  2019-02-14       Impact factor: 5.810
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.